Abstract Background Sarilumab. an IL-6 receptor antagonist. is a first-line biologic disease-modifying anti-rheumatic drug for rheumatoid arthritis. The identification of genetic biomarkers as predictors of response to sarilumab could allow for a personalized treatment strategy to improve clinical outcomes. https://www.opheliasmuse.com/